NanoViricides Inc. (NNVC)

[changes_iv]

It is quite a coincidence that yesterday I was corresponding with other interested/potential investors and JNJ, Merck and others were mentioned and the news come out:

J&J hunts for dengue fever drugs in tie-up with academia
http://www.reuters.com/article/2013/08/29/jj-dengue-idUSL6N0GU0TE20130829?type=companyNews&feedType=RSS&feedName=companyNews&rpc=43

DengueCide is a nanoviricide® that has shown very high effectiveness in an animal model of dengue virus infection. These animal studies were conducted in the laboratory of Dr. Eva Harris, Professor of Public Health and Infectious Diseases at the University of California, Berkeley. Professor Harris has developed a mouse model simulating antibody-dependent-enhancement (ADE) of dengue infection using a special laboratory mouse strain called AG129. ADE in humans is thought to lead to dengue hemorrhagic fever and is associated with a high fatality rate. In this model, infection with a dengue virus when the mice are left untreated is 100% fatal. In contrast, in the same study, animals treated with NanoViricides' DengueCide achieved an unprecedented 50% survival rate.

There is currently neither an effective drug treatment nor a vaccine for dengue virus infection. Tremendous efforts have been made for dengue vaccine development but, to date, no vaccine candidate has succeeded in clinical trials towards approval.

An orphan designation for our dengue drug candidate, if granted, is expected to help the Company assign a higher priority to its dengue drug program and undertake rapid development following the influenza drug candidates.

NanoViricides Announces that DengueCide™ Has Received Orphan Drug Designation From the US FDA --- http://www.nanoviricides.com/press%20releases/NanoViricides%20Announces%20that%20DengueCide%E2%84%A2%20Has%20Received%20Orphan%20Drug%20Designation%20From%20the%20US%20FDA.html

The efficacy of DengueCide™ *** is unprecedented ~ Dr. Eva Harris, Professor of Public Health and Infectious Diseases at the University of California, Berkeley.

The time from Phase II to market is often shorter for orphan drugs due to shorter and smaller clinical trials and FDA Fast Track designation.

Once a compound has been granted orphan designation, the odds for approval are high (82%) compared to traditional drugs (35%).

Once you approve one of many of the same "design platform technology" we will see many FDA "approvals to market" follow.


“We have clearly demonstrated that the design platform technology for nanoviricides allows development of powerful broad-spectrum antiviral drugs,” said Anil R. Diwan, PhD, President and Chairman of the Company, “We have developed a small chemical ligand that mimics both the mammalian (or a-2,6-) and avian (or a-2,3) forms of the native sialic acid receptor of influenza viruses. We can design a nanoviricide to exhibit several ligands at a single point, and each nanomicelle may exhibit several hundred ligands on its small surface. The ligands are designed to look very much like (mimic) the sialic acid to the influenza viruses, and the high density of the ligands would force the virus to land onto the nanoviricide and get destroyed by the hidden ‘tails’ of the nanomicelle that snap out and merge into the viral surface lipid coat.”

This construct, construct like LEGO pieces, boggles my mind! Watch the animation of the micelle. Do you see the referenced "hidden tails", a cross section view of the micelle, in the video animation?

Those are the deadly "tails" to a virus structure. Once the virus latches on to the ligands that were prugged-in on the "small surface" of the micelle (as described above), the hidden tails will snap out and merge into the viral surface lipid coat. Mind boggling! It is the mechanism unique to Nanoviricides, Inc. and it is patented. I have seen mechanisms for drug delivery to cancer tumor cells (you can see them in youtube) but Nanoviricides, Inc. employed mechanism is unique.

There are over 100 countries to approve "first in class" patent applications ~ 4Q 2013.

DengueCide is "the only game in town" as Dr. Anil Diwan states in the video.

Nanoviricides, Inc., "...we have the money..." for Phases I/II 2014.

A very frugal company with only (6) employees on payroll.

NOTE: If this post seems repetitive to you, ignore it. This message is intended to reach the many that will arrive to this board, on a daily basis, in anticipation of the projected Milestones that will come to pass 4Q 2013:

Nanoviricides, Inc. projected Milestones (2013) -
-cGMP/R&D Center Shelton CT integration completes ~ 4Q 2013
-Commision new cGMP plant ~ 4Q 2013 (equipment moved in/3 identical test batches)
-Receive initial results toxicology studies FluCide ~ 4Q 2013
-Prepare IND for submission to regulatory authorities ~ 4Q 2013